

























































Multivalent, Stabilized Mannose-6-Phosphates for the
Targeted Delivery of Toll-Like Receptor Ligands and
Peptide Antigens
Niels R. M. Reintjens,[a] Elena Tondini,[b] Christopher Vis,[a] Toroa McGlinn,[a]
Nico J. Meeuwenoord,[a] Tim P. Hogervorst,[a] Herman S. Overkleeft,[a] Dmitri V. Filippov,[a]
Gijsbert A. van der Marel,[a] Ferry Ossendorp,[b] and Jeroen D. C. Codée*[a]
Mannose-6-phosphate (M6P) is recognized by the mannose-6-
phosphate receptor and plays an important role in the transport
of cargo to the endosomes, making it an attractive tool to
improve endosomal trafficking of vaccines. We describe herein
the assembly of peptide antigen conjugates carrying clusters of
mannose-6-C-phosphonates (M6Po). The M6Po’s are stable M6P
mimics that are resistant to cleavage of the phosphate group
by endogenous phosphatases. Two different strategies for the
incorporation of the M6Po clusters in the conjugate have been
developed: the first relies on a “post-assembly” click approach
employing an M6Po bearing an alkyne functionality; the second
hinges on an M6Po C-glycoside amino acid building block that
can be used in solid-phase peptide synthesis. The generated
conjugates were further equipped with a TLR7 ligand to
stimulate dendritic cell (DC) maturation. While antigen presen-
tation is hindered by the presence of the M6Po clusters, the
incorporation of the M6Po clusters leads to increased activation
of DCs, thus demonstrating their potential in improving vaccine
adjuvanticity by intraendosomally active TLR ligands.
Introduction
Carbohydrates play an important role in many biological
processes, such as cell-cell communication, pathogen recog-
nition and protein folding. Mannose-6-phosphate (M6P), a d-
mannopyranose bearing a phosphate group at the C-6 position,
serves as a signaling moiety on the termini of glycan branches
mounted on newly synthesized proteins in the trans-Golgi
network and is essential for the transportation of these proteins
to the late endosomes and lysosomes. The mannose-6-
phosphate receptor (MPR), a P-type lectin, plays an important
role in this transportation through binding to M6P.[1,2] There are
two members of this lectin family: the cation-dependent
mannose-6-phosphate receptor (CD-MPR) and the cation-
independent mannose-6-phosphate receptor (CI-MPR). The
latter has a high affinity for ligands containing multiple M6Ps
due to the presence of two M6P binding domains, which can
simultaneously bind two M6Ps.[3–5] A small fraction of MPRs can
be found on the cell surface of which only CI-MPR binds and
internalizes M6P-bound substrates.[6] Therefore, the CI-MPR is an
efficient tool for targeted delivery to the endosomes, as was
shown by the conjugation of M6P analogues to acid α-
glucosidase leading to improved delivery of this enzyme in the
treatment of the lysosomal myopathy Pompe disease.[7] The
MPR has also been exploited as a drug delivery system for
cancer therapy,[8,9] for example, doxorubicin was delivered via
mannose-6-phosphate-modified human serum albumin as
carrier and N-hexanoyl-d-erythro-sphingosine with M6P-func-
tionalized liposomes.[10,11] Our group has previously reported
that a cathepsin inhibitor that is covalently attached to an M6P
cluster could effectively be delivered into the endolysosomal
pathway.[12]
The activity of peptide-based anti-cancer vaccines may be
enhanced by the targeted delivery of these antigens to antigen
presenting cells. In this context, mannosylated antigens,
destined for the mannose receptor or DC-SIGN present on
dendritic cells (DCs), have been widely explored.[13–16] We,
therefore, reasoned that conjugate vaccines in which an M6P
moiety is covalently bound to an antigenic peptide might be
targeted effectively to immune cells expressing the MPR,
leading to improved uptake and more efficient delivery to the
lysosomes where the cargo is processed for MHC loading,
ultimately resulting in enhanced antigen presentation. Since
dephosphorylation by endogenous phosphatases is one of the
potential drawbacks of the use of M6P, several stable M6P
analogues have previously been evaluated, such as a malonyl
ether, a malonate or an isosteric C-phosphonate ester.[17,18] The
C-phosphonate proved to be a stable and effective replacement
for the phosphate monoester.[19]
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We here describe the incorporation of a cluster of mannose-
6-phosphonates (M6Po) in two types of peptide antigen-
conjugates (1–8, Figure 1), wherein two different M6Po building
blocks, 9 and 10, respectively, are used to construct M6Po-
clusters and conjugate them to either the N- or the C-terminus
of a synthetic long peptide (SLP). In this study, two different
ovalbumin derived SLPs are used: DEVA5K (DEVSGLEQLESIINFE-
KLAAAAAK), which harbours the MHC-I presented epitope
SIINFEKL, and HAAHA (ISQAVHAAHAEINEAGRK), which contains
an MHC-II epitope. Our goal is to enhance the immune
response by increasing endosomal trafficking of the peptide
vaccine via the MPR which led to the design of bis-conjugates
(2, 4, 6, and 8) in which the Toll-like receptor 7 ligand (TLR7L) 2-
alkoxy-8-oxo-adenine is added at either the N- or the C-
terminus of the M6Po-SLP.[20,21] We coupled an α-configured
spacer,[12,18,22] carrying an alkyne function to the O-M6Po
building block 9 to allow for the copper mediated 1,3-dipolar
cycloaddition to azide functions incorporated in the SLP, while
C-M6Po building block 10 was used to generate the HAAHA-
conjugates via solid-phase peptide synthesis (SPPS). This
building block is a C-analogue[23] of O-M6Po, in which the
anomeric oxygen is replaced with a CH2, preventing hydrolysis
under the acidic conditions used in SPPS. An additional
advantage of this SPPS-compatible building block is the
possibility to prepare conjugates of peptides that are not
suitable for copper mediated 1,3-dipolar cycloaddition. It also
allows one to incorporate azide or alkyne click handles in
conjugate vaccine constructs that can be exploited for labelling
or visualization purposes.
We report herein the synthesis and immunological evalua-
tion of these dual conjugated peptide vaccine constructs.
Results and Discussion
Synthesis of M6Po-conjugates
The first type of O-M6Po conjugates comprises the sixfold
addition of α-propargyl mannose-6-phosphonate (O-M6Po)
building block (9) to azide containing peptides. Synthesis of the
required building block 9 started from propargyl-d-mannose 11
(Scheme 1A). As we found that the use of para-methoxybenzyl
ethers for the protection of the secondary alcohols led to the
formation of a 3,6 ether bridge when the C-6 hydroxy group
was triflated, to enable the subsequent substitution by a
phosphonate anion (see Scheme S1 in the Supporting Informa-
tion), we placed an isopropylidene group over the 2,3-cis-diol
system to prevent this intramolecular side reaction.[24,25] Thus,
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tritylation of 11 and subsequent installation of the isopropyli-
dene gave 13, of which the remaining alcohol was masked as a
p-methoxybenzyl ether to give the fully protected mannose 14.
The alkyne in 14 was protected with a TMS group using TMSCl
and nBuLi at   78 °C. Removal of the trityl in the thus obtained
15 with a catalytic amount of p-toluenesulfonic acid in CH2Cl2/
MeOH was accompanied by partial removal of the isopropyli-
dene ketal. Reinstallation of the isopropylidene and subsequent
deprotection of the mixed ketal simultaneously formed on the
primary alcohol gave 16 in 98% over three steps. Alcohol 16
was treated with Tf2O and pyridine at   40 °C
[26] and the
obtained crude triflate was added to a mixture of dimethyl
methylphosphonate and nBuLi in THF at   70 °C, yielding
compound 17 in 72% over two steps. Removal of the TMS
protecting group gave 18, which was transformed into key
building block 9 by a two-step deprotection sequence. The
deprotection of the phosphonate using TMSBr was followed by
the removal of the p-methoxybenzyl and isopropylidene groups
by treatment with AcOH/H2O at 90 °C to deliver key building
block 9 in 27% yield over 15 steps starting from d-mannose.
En route to mannose-6-phosphonate SPPS building block
10 (Scheme 1B), the trityl group of known compound 19[23] was
removed as described above to give alcohol 20 in 72% over
three steps. Conversion of 20 to the primary triflate, followed
by nucleophilic substitution with the anion of di-tert-butyl
methylphosphonate[27] gave phosphonate 21 in 72% over two
steps on 3 mmol scale.[28] Cross metathesis with methyl acrylate,
followed by the reduction of the double bond with NaBH4 and
ruthenium trichloride then resulted in compound 22.[29,30]
Hydrolysis of the obtained methyl ester, was followed by
condensation with Fmoc-l-Lys-OMe and subsequent treatment
Scheme 1. Synthesis of alkyne building blocks 9 and 10. a) i: Ac2O, pyridine; ii: propargyl alcohol, BF3 ·OEt2, 50 °C; iii: NaOMe, MeOH, 70% over three steps; b)
TrtCl, Et3N, DMF, 60 °C, 83%; c) p-toluenesulfonic acid, 2,2-dimethoxypropane, 87%; d) p-methoxybenzyl chloride, NaH, DMF, 95%; e) TMSCl, nBuLi, THF,
  78 °C, 97%; f) i: p-toluenesulfonic acid, CH2Cl2/MeOH; ii: p-toluenesulfonic acid, 2,2-dimethoxypropane; iii: 1 M HCl, EtOAc, 0 °C, 98% over three steps: g) i:
Tf2O, pyridine, CH2Cl2,   40 °C; ii: nBuLi, dimethyl methylphosphonate, THF,   70 to   50 °C, 72% over two steps; h) TBAF, THF, quant.; i) i: TMSBr, pyridine,
MeCN; ii: AcOH/H2O, 90 °C, 81% over two steps; j) i: p-toluenesulfonic acid, CH2Cl2/MeOH; ii: p-toluenesulfonic acid, 2,2-dimethoxypropane; iii: 1 M HCl, EtOAc,
0 °C, 75% over three steps; k) i: Tf2O, pyridine, CH2Cl2,   40 °C; ii: nBuLi, di-tert-butyl methylphosphonate, THF,   70 to   50 °C, 72% over two steps; l) i: methyl
acrylate, CuI, Grubbs 2nd-gen. catalyst, 1,2-dichloroethene (DCE), 60 °C; ii: NaBH4, RuCl3, MeOH, DCE, 45 °C, 72% over two steps; m) LiOH, THF/H2O, quant; n)
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of 24 with LiOH at 0 °C, which left the Fmoc group unaffected,
then delivered the key SPPS building block 10 in 80% yield.
Next, the assembly of the (O-M6Po)6-SIINFEKL conjugates
was undertaken. Immobilized peptides 25 and 28 were
prepared through standard SPPS HCTU/Fmoc chemistry using
Tentagel S Ram as solid support (Scheme 2A). The C-terminal
lysine of 25 was protected with a MMT group since we aimed
to make M6Po-peptide conjugates as well as conjugates
containing both an M6Po-cluster and a TLR7 ligand. TFA/TIS/
H2O (95 :2.5 : 2.5, v/v/v) treatment removed all protecting groups
and cleaved the peptides from the resin to give peptides 26
and 29 in 1 and 6% yield, respectively, after purification.
Alternatively, the MMT protecting group at the C-terminal lysine
of 25 was selectively deprotected using a cocktail of TFA/TIS/
CH2Cl2 (2 : 2 : 96, v/v/v). The released amine was subsequently
coupled with the spacer 33 and the Boc-protected TLR7 ligand
building block 34.[21] After deprotection, release from the resin
and RP-HPLC purification peptides 27 and 30 were obtained in
a 2% yield. Coupling of O-M6Po building block 9 to peptides
26, 27, 29 and 30 was performed using a cocktail of CuSO4,
sodium ascorbate and tris(benzyltriazolylmethyl)amine in
DMSO/H2O,
[31] with the addition of a 20 mM Tris/150 mM NaCl
Scheme 2. Synthesis of A) O-M6Po conjugates 1–4 and B) C-M6Po conjugates 5–8. a) i: 20% piperidine, DMF; ii: Fmoc SPPS cycle for K(N3)-K(N3)-K(N3)-K(N3)-K
(N3)-K(N3)-DEVSGLEQLESIINFEKLAAAAAK; iii: 20% piperidine, DMF; iv: Ac2O, DIPEA, DMF; b) TFA/TIS/H2O (95 :2.5 : 2.5, v/v/v), 3 h; c) RP-HPLC; d) 9, 20 mM Tris/
150 mM NaCl buffer, CuSO4/NaAsc/TBTA, H2O/DMSO; e) TFA/TIS/CH2Cl2 (2 : 2 : 96, v/v/v); f) i: (2-(2-(Fmoc-amino)ethoxy)ethoxy)acetic acid, HCTU, DIPEA, DMF; ii:
20% piperidine, DMF; iii: 4-((2-butoxy-6-((tert-butoxycarbonyl)amino)-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)benzoid acid, HCTU, DIPEA, DMF; g) i: 20%
piperidine, DMF; ii: Fmoc SPPS cycle for DEVSGLEQLESIINFEKLAAAAAK-K(N3)-K(N3)-K(N3)-K(N3)-K(N3)-K(N3); iii: 20% piperidine, DMF; h) Ac2O, DIPEA, DMF; i) i:
20% piperidine, DMF; ii: Fmoc SPPS cycle for ISQAVHAAHAEINEAGRK; iii: 20% piperidine, DMF; iv: 10, HCTU, DIPEA, DMF; v: 5× repeat of iii and iv; vi: 20%
piperidine, DMF; vii: Ac2O, DIPEA, DMF; j) AcOH/TFE/CH2Cl2 (1 : 2 : 7, v/v/v); k) i: 20% piperidine, DMF; ii: 10, HCTU, DIPEA, DMF; iii: 5× repeat of i and ii; iv: 20%
piperidine, DMF; v: Fmoc SPPS cycle for ISQAVHAAHAEINEAGRK; vi: 20% piperidine, DMF. Yield peptides and conjugates: 26) 4.6 mg, 1%; 27) 4.0 mg, 2%; 29)
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buffer. After RP-HPLC, conjugates 1–4 were obtained in 5%
(0.3 mg), 18% (0.9 mg), 18% (1.0 mg) and 31% (3.3 mg) yield
respectively.
The HAAHA peptide contains two histidines, which can
coordinate to copper and thereby inhibit the reduction of CuII
to CuI.[32] Therefore, conjugates 5–8 were generated by an
online SPPS synthesis (Scheme 2B) using C-M6Po building block
10, which is equipped with acid-labile protecting groups that
can be removed at the end of the SPPS concomitantly with all
other acid-labile peptide protecting groups and release of the
peptide from the resin. Tentagel S Ram resin was elongated
with ISQAVHAAHAEINEAGRK using automated SPPS, of which
the lysine(MMT) at the C terminus will be used for elongation at
a later stage of the synthesis. Six consecutive coupling and
Fmoc removal cycles with building block 10 gave immobilized
peptide 31. Peptide 32, bearing the C-M6Po cluster at the C-
terminal end, was generated by assembling the hexa-C-M6Po
peptide through manual couplings of building block 10,
followed by automated SPPS to assemble the rest of the
peptide. Immobilized and protected peptides 31 and 32 were
deprotected and simultaneously cleaved from the resin with
the TFA/TIS cocktail to provide conjugates 5 (13.3 mg) and 7
(3.1 mg) after purification by RP-HPLC in 10 and 8% yield,
respectively, demonstrating the suitability of 10 for SPPS. To
obtain conjugate 6, bearing the TLR7 ligand, the MMT group in
31 was selectively removed with a cocktail of AcOH/TFE/CH2Cl2
(1 : 2 : 7, v/v/v). The obtained free amine was elongated with
spacer 33 and Boc-protected TLR7 ligand building block 34 to
give conjugate 6 (11.0 mg) in 2% yield, after removal of all the
protecting groups, cleavage from the resin and RP-HPLC
purification. The same sequence of events was applied to the
N-terminal amine in immobilized peptide 32 to afford con-
jugate 8 (17.0 mg) in 8% yield.
Immunological evaluation
We assessed the capacity of the conjugates 1–8 to induce
maturation of dendritic cells (DCs) and stimulate antigen
presentation (Figure 2). In these assays reference compounds
35–40, lacking the mannose-6-phosphonate clusters, were used
as a control (Scheme S2). The activation of DCs can be
measured by the detection of the production of interleukin-12
(IL-12).
First, the O-M6Po conjugates 1–4 were evaluated (Fig-
ure 2A). To this end, murine bone marrow/derived DCs were
stimulated for 24 hours with the compounds and the amount
of secreted IL-12 was measured in the supernatant. As
expected, conjugation with solely a cluster of M6Po (as in
conjugates 1 and 3) does not induce DC maturation. In contrast,
the TLR7 ligand SLP conjugates (36 and 37) induce IL12
production due to stimulation of the TLR7 receptor.
Interestingly, the conjugates carrying the M6Po-cluster and
the TLR7 ligand (2 and 4) induced a stronger activation of the
DCs than their counterparts solely bearing a TLR7 ligand (i. e.,
SLP-conjugates 36 and 37). The position of the M6Po-clusters
and TLR7 ligand in these conjugates did not seem to influence
the activity of the conjugates. Similar effects were observed for
the conjugates 6 and 8 with the C-M6Po-clusters, indicating
that the C-mannosyl-6-C-phosphonate is an adequate mimic of
its O-mannosyl counterpart and that the enhanced stimulatory
effect is independent of the peptide sequence (Figure 2B, see
also Figure S1). Overall this indicates that conjugation of the
M6Po-cluster to a peptide antigen adjuvanted with a TLR7
ligand enhances DC maturation by improving uptake of the
conjugate and/or trafficking of the conjugates to the endo-
somally located TLR7 receptor.
Processing of the two peptides was investigated by
assessing presentation of the SIINFEKL epitope on MHC-I the
DCs to CD8+ T cells and presentation of the helper epitope
(HAAHA) to CD4+ T cells. For the former assay, the hybridoma
(B3Z) CD8+ T cell line was used, while the latter employed the
OTIIZ hybridoma CD4+ T cell line. As can be seen in Figure 2C
and D, attachment of the TLR7 ligand to the SLPs led to the
enhanced presentation of the antigens (e.g., 35 vs. 36/37 and
38 vs. 40), however the inclusion of the M6Po-clusters
hampered presentation through both the MHC class I and MHC
class II pathways (e.g., 36 vs. 4, 37 vs. 2 and 40 vs. 6). This
indicates that the conjugation of M6Po-clusters affects intra-
cellular trafficking or processing of the peptides.
Conclusion
In conclusion, we have described the development of two
mannose-6-C-phosphonate (M6Po) building blocks which allow
for stabilized M6P-analogues to be incorporated in peptide
sequences to target the M6P receptor. To prevent dephosphor-
ylation by endogenous phosphatases, the O-phosphate in the
naturally occurring mannose-6-phosphate was replaced by a C-
phosphonate moiety. The first building block carries an O-
propargyl group at the anomeric center of the mannose-6-C-
phosphonate, which allows for the incorporation of the M6Po
in peptide sequences through an azide-alkyne click reaction.
The second building block, a C-mannoside, was designed and
synthesized for application in solid-phase peptide synthesis.
The acid-stable anomeric linkage and protecting groups used
enabled the streamlined in-line incorporation of the building
block during SPPS. With the building blocks, various peptide
conjugates were assembled, containing either an MHC-I or an
MHC-II epitope, an M6Po-cluster presenting six mannose-6-
phosphonates, and a TLR7 ligand. Although immunological
evaluation has shown that conjugation of the M6Po-clusters
inhibits antigen presentation, the ability of the TLR7 ligand
conjugates to induce DC maturation was significantly improved.
While the M6Po clusters effectively trafficked the conjugates to
the endosome, where the conjugates interacted with TLR7
receptor, the processing of the conjugates was impeded by the
M6Po-clusters. Future conjugates will be designed featuring
cleavable linkers that allow for the release of the clusters during
endolysosomal processing, effectively liberating the incorpo-
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Figure 2. M6Po conjugation enhances DC activation of the TLR7 ligand conjugates but inhibits antigen presentation. A) Murine bone-marrow-derived
dendritic cells were stimulated in triplicate for 24 h with the indicated conjugates of the DEVA5K peptide. The induction of DC maturation was analyzed by
measuring IL-12 production with sandwich ELISA specific for the IL-12p40 subunit. The bars represent the standard deviation of the mean of the triplicates. B)
The induction of IL-12p40 of the DEVA5K and the HAAHA conjugates was compared by stimulating bone-marrow-derived dendritic cells for 24 h, followed by
sandwich ELISA. C) and D) Antigen uptake and presentation to T cells was measured by incubating dendritic cells in duplicate with the indicated compounds
for 3 h, followed by incubation with the reporter hybridoma T cell lines. The SIINFEKL-specific hybridoma T cell line B3Z served as readout for the DEVA5K
peptide, while the OTIIZ hybridoma cell line was used to detect presentation of the HAAHA epitope. B3Z or OTIIZ activation was determined by colorimetric
reaction of the lacZ reporter enzyme. Results are representative of three independently performed experiments. The statistical differences between
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